Company Overview
Snapshot
Founded in April 2020 by Prof. Yaniv Erlich, Prof. Greg Hannon, and Shaul Ilan, Eleven Therapeutics operates with 11–50 employees. The company has raised $25.9 million across three funding rounds from three investors. In January 2024, Eleven Therapeutics appointed Dr. Paloma H Giangrande as Chief Technology Officer.
Business overview
Eleven Therapeutics is a startup focused on advancing mRNA therapeutics. The company's core technology revolves around its xRNA modality-based pipeline, designed to create extended-release mRNA therapeutics (xRNA). These therapeutics target unmet medical needs across metabolic, hematologic, and infectious disease areas. Eleven Therapeutics utilizes its proprietary high-throughput platform, TERÅ, to screen thousands of xRNA molecules to identify elements with superior stability and safety for chronic therapeutic applications, including fibrotic disorders. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, and is involved in drug development and molecular biology.
Strategic signal
In January 2024, Eleven Therapeutics announced a research and development agreement with Dong-A ST for RNA-based gene therapy, following a partnership with Novo Nordisk in July 2023 to develop nucleic acid therapeutics. These collaborations signal strong external validation of Eleven Therapeutics' xRNA platform and its potential to attract significant pharmaceutical partners, indicating a positive trajectory for its therapeutic development and market entry.
Log in to access full profile ›Company Intelligence Q&A
- What was a key leadership appointment at Eleven Therapeutics?
- In January 2024, Eleven Therapeutics welcomed Dr. Paloma H Giangrande as Chief Technology Officer, a strategic move to bolster its scientific leadership.
- Which company did Eleven Therapeutics partner with for nucleic acid therapeutics?
- In July 2023, Eleven Therapeutics partnered with Novo Nordisk to develop nucleic acid therapeutics, focusing on advancing their respective pipelines.
- What was the nature of the agreement between Eleven Therapeutics and Dong-A ST?
- In January 2024, Eleven Therapeutics signed an R&D agreement with Dong-A ST for RNA-based gene therapy, indicating a collaboration on novel therapeutic approaches.
- When did Eleven Therapeutics raise its seed funding round?
- In August 2022, Eleven Therapeutics raised $22 million in seed funding. Investors included NFX Capital and Harel Insurance & Finance.
- What was the collaboration between Twist Bioscience and Eleven Therapeutics?
- In February 2022, Twist Bioscience and Eleven Therapeutics collaborated to create a replicon for the development of antiviral tools.